Sign In

The AASLD Liver Meeting 2017, Washington DC, October 20-24

Nuclear Receptors and Liver

Date/Time

  • Saturday, October 21, 8 am - 5 pm

Continuing Education

  • CME - 7.50 AMA PRA Category 1 Credits™ 
  • MOC - 7.50 Hours

Program Chairs

  • Li Wang, PhD
  • Wendong Huang, PhD

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss the critical roles of nuclear receptors in liver physiology.
  • Recognize the impact of nuclear receptors in the development of hepatic disease.
  • Identify new therapeutic approaches to treat liver diseases by targeting nuclear receptors.

Session Description/Needs Statement

Nuclear receptors constitute a unique superfamily of transcription factors important to a broad aspect of liver physiology and pathophysiology. Recent advances in using obeticholic acid (OCA), an analog of nuclear receptor FXR natural ligand CDCA to treat primary biliary cirrhosis (PBC), shed lights on the great potential for targeting nuclear receptors in the treatment of liver diseases. This symposium will bring together basic researchers and clinical investigators to promote nuclear receptor research based therapeutics.

Session I: Basic Mechanisms of Nuclear Receptor Function

Moderators: Li  Wang, PhD and Wendong  Huang, PhD

  • 8-8:05 am
    Welcome and Overview
    Li  Wang, PhD and Wendong  Huang, PhD
  • 8:05- 8:30 am
    Nuclear Receptors and Cross-Talk Between Gut and Liver
    David Moore, PhD
  • 8:30-8:55 am
    Nuclear Receptors At the Crossroads of Metabolism and Inflammation
    Peter Tontonoz, MD, PhD
  • 8:55-9:20 am
    Mechanisms of Gene Regulation in the Liver; The Central Role Chromatin and Chromatin Reorganization in the Interaction of Transcription Factors with Regulatory Elements
    Gordon L. Hager, PhD
  • 9:20-9:45 am
    Genetic Variation in PPARα Gene Regulation in Normal and Fatty Liver
    Raymond Soccio, MD, PhD
  • 9:45 am-10:05 am
    Panel Discussion
  • 10:05-10:15 am
    Break

Session II: Nuclear Receptors in Hepatic Lipid Metabolism

Moderators: Youngmin A. Lee, MD and Lisa  Zhang, MD, PhD

  • 10:15-10:40 am
    LRH-1 Structure and Ligand in Hepatic Metabolism
    Holly A. Ingraham, PhD
  • 10:40-11:05 am
    Nuclear Receptor HNF4a in Hepatic Lipid Metabolism
    Frances M. Sladek, PhD
  • 11:05-11:30 am
    Intestine-liver Crosstalk in the Pathogenesis of NAFLD
    Frank J. Gonzalez, MD
  • 11:30-11:50 am
    Panel Discussion
  • 11:50-1:10 pm
    Intermission: Meet-the-Professor Luncheons (Basic)
    *Ticketed Session

Session III: Nuclear Receptors Crosstalk with Non-coding RNAs

Moderators: Heather L. Francis, PhD and Huiping  Zhou, PhD

  • 1:10-1:35 pm
    LncRNA and SHP Crosstalk in Liver Metabolism
    Li Wang, PhD
  • 1:35-2:00 pm
    SETDB2 Links Glucocorticoid and Lipid Metabolism Through SREBPs
    Timothy F. Osborne, PhD
  • 2-2:25 pm
    Bile Acid Receptors and miRNAs to Suppress NAFLD
    Wendong Huang, PhD
  • 2:25-2:45 pm
    Panel Discussion
  • 2:45-2:55 pm
    Break

Session IV: Nuclear Receptors as Therapeutic Targets

Moderators: Kari  Nejak-Bowen, PhD and Grace L. Guo, PhD

  • 2:55-3:20 pm
    Nuclear Receptors in Adult Liver Diseases and Therapeutic Potential
    Michael H. Trauner, MD, FAASLD
  • 3:20-3:45 pm
    Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders
    Stefano Fiorucci, MD
  • 3:45-4:10 pm
    Nuclear Receptors in Pediatric Liver Diseases and Therapeutic Potential
    Saul J. Karpen, MD, PhD, FAASLD
  • 4:10-4:35 pm
    Targeting Xenobiotic Receptors PXR and CAR for Metabolic Diseases
    Wen Xie, MD, PhD
  • 4:35-4:55 pm
    Panel Discussion
  • 4:55-5 pm
    Concluding Remarks